Aspiriant LLC Sells 380 Shares of CVS Health Co. (NYSE:CVS)

Aspiriant LLC lessened its stake in CVS Health Co. (NYSE:CVS) by 10.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,287 shares of the pharmacy operator’s stock after selling 380 shares during the period. Aspiriant LLC’s holdings in CVS Health were worth $262,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. SOA Wealth Advisors LLC. increased its holdings in shares of CVS Health by 4.9% during the fourth quarter. SOA Wealth Advisors LLC. now owns 2,859 shares of the pharmacy operator’s stock worth $226,000 after buying an additional 133 shares in the last quarter. Apella Capital LLC increased its holdings in shares of CVS Health by 4.2% in the fourth quarter. Apella Capital LLC now owns 3,378 shares of the pharmacy operator’s stock valued at $272,000 after purchasing an additional 136 shares in the last quarter. Prairie Sky Financial Group LLC increased its holdings in shares of CVS Health by 4.1% in the fourth quarter. Prairie Sky Financial Group LLC now owns 3,612 shares of the pharmacy operator’s stock valued at $285,000 after purchasing an additional 141 shares in the last quarter. WealthShield Partners LLC increased its holdings in shares of CVS Health by 3.2% in the fourth quarter. WealthShield Partners LLC now owns 4,498 shares of the pharmacy operator’s stock valued at $355,000 after purchasing an additional 141 shares in the last quarter. Finally, Sugarloaf Wealth Management LLC boosted its stake in CVS Health by 9.5% in the fourth quarter. Sugarloaf Wealth Management LLC now owns 1,639 shares of the pharmacy operator’s stock valued at $129,000 after acquiring an additional 142 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In related news, Director Edward J. Ludwig acquired 1,000 shares of CVS Health stock in a transaction dated Thursday, May 2nd. The shares were purchased at an average price of $53.88 per share, for a total transaction of $53,880.00. Following the completion of the transaction, the director now directly owns 21,630 shares in the company, valued at approximately $1,165,424.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.24% of the company’s stock.

CVS Health Trading Up 0.3 %

Shares of CVS Health stock opened at $60.63 on Thursday. The firm has a market cap of $76.11 billion, a PE ratio of 10.65, a PEG ratio of 0.58 and a beta of 0.53. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.81 and a quick ratio of 0.61. CVS Health Co. has a 1 year low of $52.77 and a 1 year high of $83.25. The company has a 50 day simple moving average of $60.16 and a two-hundred day simple moving average of $70.45.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). The firm had revenue of $88.44 billion during the quarter, compared to the consensus estimate of $89.33 billion. CVS Health had a return on equity of 13.53% and a net margin of 2.03%. The business’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.20 EPS. Analysts expect that CVS Health Co. will post 7.02 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Robert W. Baird began coverage on shares of CVS Health in a research report on Thursday, May 30th. They set a “neutral” rating and a $61.00 price target on the stock. SVB Leerink reiterated a “market perform” rating and issued a $60.00 price target (down from $87.00) on shares of CVS Health in a research note on Wednesday, May 1st. Mizuho lowered their price target on shares of CVS Health from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Thursday, May 2nd. UBS Group lowered shares of CVS Health from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $85.00 to $60.00 in a research note on Thursday, May 2nd. Finally, Piper Sandler boosted their price objective on shares of CVS Health from $93.00 to $94.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Eleven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $75.05.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.